Side-by-side comparison of AI visibility scores, market position, and capabilities
E-prescribing, medication history, and patient safety platform processing hundreds of millions of Rx transactions annually. Rockville MD; founded 2000; embedded in hundreds of EHR and clinical workflow platforms; EPCS compliance and medication history retrieval improve prescribing safety for 500K+ providers.
DrFirst is a health IT company that has been at the forefront of e-prescribing and medication management since its founding in 2000. Headquartered in Rockville, Maryland, DrFirst provides e-prescribing for controlled substances (EPCS), medication history retrieval, clinical decision support, and patient medication adherence tools to hospitals, physician practices, long-term care facilities, and health IT vendors. The company processes hundreds of millions of prescription transactions annually and is embedded in a wide range of EHR and clinical workflow platforms through its APIs and SDK integrations.\n\nDrFirst's flagship EPCS solution was among the earliest to achieve DEA compliance for electronic prescribing of controlled substances, a capability that has become essential as regulatory requirements and clinical adoption have expanded across all states. The company's medication history service aggregates pharmacy and payer claims data to give providers a more complete view of a patient's actual medication use, supporting medication reconciliation at transitions of care and reducing adverse drug events. DrFirst also offers Backline, a secure clinical communication platform for care team messaging.\n\nDrFirst occupies a specialized but critical position in the health IT ecosystem, providing medication-related infrastructure that EHR vendors embed in their platforms rather than build independently. This embedded model gives DrFirst broad distribution across the provider market and creates sticky, long-term customer relationships. The company has invested in expanding its clinical intelligence capabilities, including AI-driven prior authorization for specialty medications and smart alerts that surface relevant clinical guidance at the point of prescribing.
Armonk NY hybrid cloud and enterprise AI (NYSE: IBM) at $62.8B revenue; $6B+ generative AI bookings, record $12.7B free cash flow 2024, DataStax acquisition for watsonx vector database competing with Microsoft Azure for enterprise AI.
International Business Machines Corporation (IBM) is an Armonk, New York-based global technology and consulting company — publicly traded on the New York Stock Exchange (NYSE: IBM) as an S&P 500 component — providing hybrid cloud infrastructure, artificial intelligence software, and enterprise IT consulting through approximately 270,300 employees in 170 countries with $62.8 billion in annual revenue. Founded on June 16, 1911, as Computing-Tabulating-Recording Company through a merger orchestrated by financier Charles Ranlett Flint, renamed IBM in 1924 under Thomas Watson Sr., IBM has undergone multiple strategic transformations over its 110+ year history: building the System/360 mainframe platform (1964), launching the IBM PC (1981), selling the PC division to Lenovo (2005, $1.75B), and completing the $34 billion Red Hat acquisition (2019) that repositioned IBM as a hybrid cloud platform company. CEO Arvind Krishna (appointed April 2020) has focused IBM's strategy on three areas: hybrid cloud (powered by Red Hat OpenShift, the enterprise Kubernetes platform), AI (the watsonx platform for enterprise AI model development and deployment), and enterprise consulting. Under Krishna, IBM recorded $12.7 billion in free cash flow in 2024 (a company record), surpassed $6 billion in generative AI bookings since June 2023, and saw the stock price double — trading at all-time highs through 2024-2025. IBM announced the DataStax acquisition in 2025 to deepen watsonx's data layer with AstraDB (vector database for AI applications), DataStax Enterprise (Apache Cassandra), and Langflow (low-code AI agent development).
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.